Use of fondaparinux in a pregnant woman with pulmonary embolism and heparin-induced thrombocytopenia

Medical Science Monitor

Volumn 17, Issue 5, 2011, Pages

  Ciurzyński, Michał ^a   Jankowski, Krzysztof ^a   Pietrzak, Bronisława ^a   Mazanowska, Natalia ^a   Rzewuska, Ewa ^a   Kowalik, Robert ^a   Pruszczyk, Piotr ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Fondaparinux; Heparin induced thrombocytopenia; Pregnancy; Pulmonary embolism

Indexed keywords

ENOXAPARIN; FONDAPARINUX; HEPARIN;

ADULT; ARTICLE; CASE REPORT; DRUG EFFICACY; DRUG USE; DRUG WITHDRAWAL; FEMALE; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; LUNG EMBOLISM; PREGNANCY; PREGNANT WOMAN; THIRD TRIMESTER PREGNANCY; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 79955942157     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.881753     Document Type: Article

References (22)

1. Heit JA, Kobbervig CE, James AH et al: Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population based study. Ann Intern Med, 2005; 36: 697-706
2. Rutherford SE, Phelan JP: Deep venous thrombosis and pulmonary embolism in pregnancy. Obstet Gynecol Clin North Am, 1991; 18: 345-70
3. Sullivan EA, Ford JB, Chambers G, Slaytor EK: Maternal mortality in Australia, 1973-1996. Aust N Z J Obstet Gynaecol, 2004; 44: 452-57
4. Bates SM, Greer IA, Pabinger I et al: Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy. Chest, 2008; 133(Suppl.6): 844S-886S
5. Torbicki A, Perrier A, Konstantinides S et al: Guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J, 2008; 29: 2276-15
6. Warkentin TE, Greinacher A, Koster A, Lincoff AM: Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physician Evidence-Based Clinical Practice Guidelines (8th Edition). Chest, 2008; 133: 340S-80S
7. Warkentin TE, Levine MN, Hirsh J et al: Heparin-induced thrombocytopenia in patients treated with low-molecular weight heparin or unfractionated heparin. N Eng J Med, 1995; 332: 1330-35
8. Sanson BJ, Lensing AW, Prins MH et al: Safety of low-molecular-weight heparin in pregnancy: a systemic review. Thromb Haemost, 1999; 81: 668-72
9. Lepercq J, Conrad J, Borel-Derlon A et al: Venous thromboembolism during pregnancy: a retrospective study of enoxaparin safety in 624 pregnancies. Br J Obstet Gynaecol, 2001; 108: 1134-40
10. Ellison J, Walker ID, Greer IA: Antenatal use of enoxaparin for prevention and treatment of thromboembolism in pregnancy. Br J Obstet Gynaecol, 2000; 107: 1116-21
11. Greer IA, Nelson-Piercy C: Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism. Blood, 2005; 106: 401-7
12. Chong BH, Magnani HN: Danaparoid for the treatment of heparininduced thrombocytopenia. In: Warkentin TE, Greinacher A (eds.), Heparin-induced thrombocytopenia. 4Pth ed. New York, NY: Informa Healthcare USA, 2007; 319-43
13. Magnani HN, Gallus A: Heparin-induced thrombocytopenia (HIT): a roport of 1,478 clinical outcomes of patients treated with danaparoid (Orgaran) from 1982 to mid-2004. Thromb Haemost, 2006; 95: 967-81
14. Myers B, Westby J, Strong J: Prophylactic use of danaparoid in high-risk pregnancy with heparin-induced thrombocytopenia-positive skin reaction. Blood Coagul Fibrynolysis, 2003; 14: 485-87
15. Schindewolf M, Lindhoff-Last E: Alternative anticoagulation with danaparoid in two pregnancies in a patient with former heparin-induced thrombocytopenia (HIT), homozygous factor V Leiden mutation, a history of venous thrombosis and recurrent pregnancy losses. Thromb Haemost, 2008; 99: 776-78
16. Mehta R, Golichowski A: Treatment of heparin induced thrombocytopenia and thrombosis during the first trimester of pregnancy. J Thromb Haemost, 2004; 2: 1665-66
17. Young SK, Al-Mandhiry HA, Vaida ST et al: Successful use of argatroban during the third-trimester of pregnancy: case report and review of literature. Pharmacotherapy, 2009; 28: 1532-36
18. Harenberg J: Treatment of a woman with lupus and thromboembolism and cutaneous intolerance to heparins using fondaparinux during pregnancy. Thromb Res, 2007; 119: 385-88
19. Dampfle CE: Minor transplacental passage of fondaparinux in vivo. N Engl J Med, 2004; 350: 1914-15
20. Lagrange F, Brun JL, Vergnes MC et al: Fondaparinux sodium does not cross the placental barrier: study using the in vitro human dually perfused cotyledon model. Clin Pharmacokinet, 2002; 41: 47-49
21. Mazzolai L, Hohlfeld P, Spertini F et al: Fondaparinux is a safe alternative in case of heparin intolerance during pregnancy. Blood, 2006; 108: 1569-70
22. Warkentin TE, Maurer RH, Aster RH: Heparin-induced thrombocytopenia associated with fondaparinux. N Engl J Med, 2007; 356: 2653-54